Aurobindo Pharma's Telangana API Facility Receives VAI Status from USFDA

Aurobindo Pharma revealed that the United States Food and Drug Administration (USFDA) has provided an establishment inspection report (EIR) to its subsidiary's active pharmaceutical ingredient (API) facility in Telangana, categorizing it as voluntary action indicated (VAI).

The Unit 2 API manufacturing plant belongs to Apitoria Pharma Pvt Ltd, which is a fully-owned subsidiary of the company. It is situated in Gaddapotharam village IDA, within the Sanga Reddy district of Telangana. The facility was inspected by the USFDA from September 23 to September 27, 2024.

Last month, Apitoria Pharma's other API manufacturing plant, Unit V, was noted by the USFDA with two observations categorized as procedural. Aurobindo Pharma stated that it would address the remarks within the designated time period. The US pharmaceuticals regulator examined the facility between December 9 and December 17, 2024.

Last week, the brokerage Investec launched a FAST (a strongly held short-term analyst recommendation) on pharmaceutical company Aurobindo Pharma Ltd. with a target price of ?1,930. The brokerage stated that the latter part of this financial year will outperform the first, which will aid in the re-evaluation of the stock.

Aurobindo has the greatest contribution from the export market among Indian pharmaceutical firms, and a falling rupee will be advantageous for the company, according to Investec's report. On Tuesday, January 28, Aurobindo Pharma shares were trading down 1.17% at ?1,162.45 each at 10:10 am. The stock has decreased by 17.21% over the past six months.